tbuckley/cabot-search huggingface dataset:
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to <i>clusterin</i>, in patients with prostate cancer prior to radical prostatectomy
Authors: K. N. Chi, E. Eisenhauer, L. Fazli, E. C. Jones, J. Powers, D. Ayers, S. L. Goldenberg, M. E. Gleave
Journal: Journal of Clinical Oncology (2004)

3033 Background: The clusterin gene encodes a chaperone protein that promotes cell survival. Clusterin is expressed in a variety of cancers including prostate, increases in response to after androgen abaltion and other apoptotic stimuli, and confers a resistant phenotype in pre-clinical models . OGX-011 (Oncogenex Technologies Inc) is a 2nd generation antisense complimentary to clusterin mRNA that inhibits expression of clusterin in xenograft models and thereby increases sensitivity to therapy. The objective of this first-in-man study was to determine phase II dose based on optimal target regulation effect in addition to standard toxicity parameters. Methods: Patients having localized prostate cancer with high-risk features and candidates for prostatectomy were enrolled to this dose escalation trial. OGX-011 was given by IV infusion over 2 hrs at a starting dose of 40mg on days 1, 3, 5, 8, 15, 22, and 29. Buserelin and flutamide were started on day 1. Prostatectomy was performed day 30–36. OGX-011 plasma PK and prostate tissue concentrations were determined. Prostate tissues, serial samples of peripheral blood mononuclear cells, and serum were assessed for clusterinexpression. Results: 20 patients have been enrolled to 6 cohorts with doses of OGX-011 up to 640mg. Toxicity has been limited to grade 1 or 2, including fevers, rigors, fatigue and transient AST and ALT elevations. Plasma PK analysis showed linear increases in AUC with a t1/2 of approximately 2 hrs. OGX-011 prostate tissue concentrations increased with dose to a mean of 2.30 ug/g (∼300nM) at 480mg dosing. Dose dependent decreases in prostate tumor clusterin expression were observed by immunohistochemistry (IHC) and in situ hybridization. By IHC, mean % cancer cells staining for 0 intensity at 480mg was 49.2% (SE 9.0) compared with 3.3–14.5% for lower dose levels. Conclusions: OGX-011 is well tolerated and can inhibit clusterin expression in prostate cancers. Dose escalation and additional PD assessments continue. Supported by a grant from the U.S. Department of Defense and coordinated by the NCIC-CTG. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration OncoGenex Technologies OncoGenex Technologies OncoGenex Technologies Abbott; Aventis OncoGenex Technologies
Phase I trial of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases.
Authors: Lin Zhou, Jiazhuo He, Weijie Xiong, Qin Yu, Jin Xiang, Maozhi Liang, Yongmei Liu, Zhenyu Ding, Youling Gong, Meijuan Huang, Jiang Zhu, Lu Li, Yongsheng Wang, Mei Hou, Li Ren, You Lu
Journal: Journal of Clinical Oncology (2014)

8110 Background: Icotinib has been demonstrated to provide similar efficacy to gefitinib in non-small cell lung cancer (NSCLC) patients. This phase I trial (NCT01516983) evaluated the dose-escalation toxicity of icotinib combined with whole brain radiotherapy (WBRT) in EGFR-mutated NSCLC patients with brain metastases, and cerebrospinal fluid (CSF) penetration rates of icotinib were assessed in the dose-escalation. Methods: The cohorts were constructed with a 3 + 3 design, and the dose-escalation schedule of icotinib was set as 125mg tid, 250mg tid, 375mg tid, 500mg tid, and 625mg tid. Icotinib was started 7 days before and continued during WBRT (37.5Gy/15f/21d), and maintained until disease progression or intolerable toxicities occurred. The blood and CSF samples were obtained at 7:30-8:00 a.m. just before the administration of icotinib on day 7 (before WBRT), day 29 (after WBRT) and day 57 of therapy. Results: Fifteen patients were enrolled in this trial. The treatment-related toxicities were generally mild (CTC AE grade 1-2), and the most frequent treatment-related toxicities were alopecia (15/15), acne-like rash (14/15) and nausea (11/15). At dose level of 500mg tid, 3 out of 6 patients experienced dose-limiting toxicity including 1 grade 3 alanine aminotransferase elevation and 2 grade 3 nausea, after reducing the dose of icotinib to 250mg tid, these toxicities disappeared. The mean icotinib CSF penetration rate was 4.04% (range: 1.23%-9.71%), and there was a good correlation between plasma and CSF concentrations (R2=0.577, P<0.001). There were no statistical differences in plasma concentrations, CSF concentrations, and penetration rates of icotinib between day 7, day 29, and day 57. However, CSF concentration and penetration rate of icotinib were much higher at dose of 375mg tid (mean CSF concentration: 154.09ng/ml, P<0.001; mean penetration rate: 7.06%, P<0.001). Conclusions: WBRT with concurrent and maintenance icotinib (125mg tid-375mg tid) were well tolerated in EGFR-mutated NSCLC patients with brain metastases. WBRT might not increase penetration rate of icotinib, however, there were the highest CSF concentration and penetration rate at dose of 375mg tid. Clinical trial information: NCT01516983.
STRESS INDUCED CARDIOMYOPATHY TRIGGERED BY CHEMOTHERAPY: WHEN SHOULD CANCER THERAPY BE RESTARTED?
Authors: Dana Giza, Juan Lopez-Mattei, Peter Kim, Ezequiel D. Muñoz Gonzalez, Joerg Herrmann, Gloria Iliescu, Eric Yang, Saamir Hassan, Cezar Iliescu
Journal: Journal of the American College of Cardiology (2017)
Myeloma Canada Research Network (MCRN)-001 ASCT Study of Busulfan + Melphalan (BuMel) Conditioning Followed By Lenalidomide (Len) Maintenance: Updated Results Including Serial Minimal Residual Disease (MRD) and Involved Serum Hevylite™ Chain (HLC) Ratio Assessments
Authors: Donna Reece, Giovanni Piza Rodriguez, Mariela Pantoja, Darrell White, Christopher P. Venner, Julie Stakiw, Michael Sebag, Terrance Comeau, Kevin W. Song, Jean Roy, Martha L Louzada, Arleigh McCurdy, Vishal Kukreti, Suzanne Trudel, Anca Prica, Rodger Tiedemann, Christine Chen, Harminder Paul
Journal: Blood (2016)
Chronic Myeloid Leukemia (CML) Treatment in Brazil: Results of the Rio Grande do Sul Cooperative Group for Treatment of CML.
Authors: Laura M. Fogliatto, Ines Guterres, Marcelo Z. Capra, Mario S. Fernandes, Marisa Schaan, Tania Hellwig, Aletea Zago, Marco Schilling, Denise Almeida, Sabrina Wisinteiner, Roque Lorandi, Adriana Winck, Adriana Zardo, Lucia M.R. Silla
Journal: Blood (2006)
Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity : relationship with gut microbiome richness and ecology [plus Supplementary data]
Authors: M.C. Dao, A. Everard, J. Aron-Wisnewsky, N. Sokolovska, E. Prifti, E.O. Verger, B.D. Kayser, F. Levenez, J. Chilloux, L. Hoyles, M.E. Dumas, S.W. Rizkalla, J. Dore, P.D. Cani, K. Clement, S. Le Mouhaër, A. Cotillard, S.P. Kennedy, N. Pons, M. Almeida, B. Quinquis, N. Galleron, J.M. Batto, P. Renault, Jean-Daniel Zucker, S. Dusko Ehrlich, H. Blottière, M. Leclerc, C. Juste, T. De Wouters, P. Lepage
Journal: Gut (2016)
Distinct Stress Responses of Bone Marrow Stromal Cell Subgroups Defined by Unbiased Single-Cell Mass-Cytometry Analysis
Authors: Nicolas Severe, Murat Karabacak, Ninib Baryawno, Karin Gustafsson, Youmna Sami Kfoury, Mehmet Toner, David T. Scadden
Journal: Blood (2016)
Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).
Authors: Jesùs F. San-Miguel, Philippe Moreau, Sung-Soo Yoon, Meletios A. Dimopoulos, Vânia Tietsche de Moraes Hungria, Wieslaw W. Jedrzejczak, Ashraf el Ghandour, Paolo Corradini, Andreas Günther, Meral Beksac, Kwee Yong, Jae Hoon Lee, Sagar Lonial, Jian Hou, Hermann Einsele, Monika M Wroclawska-Swacha, Hans-Jochen Weber, Priscille M. Bourquelot, Paul Gerard Guy Richardson
Journal: Journal of Clinical Oncology (2012)

e18572^ Background: Multiple myeloma (MM) is an incurable disease, and significant unmet need remains in the relapsed (Rel) and refractory (Ref) settings. Thus, effective agents and combination strategies are of continued interest. Clinical activity was observed in a phase Ib study of the novel pan-deacetylase inhibitor panobinostat (PAN) and the proteasome inhibitor bortezomib (BTZ) in patients (pts) with Rel or Rel/Ref MM. We report the results of a blinded safety analysis from PANORAMA 1, an international, randomized, double-blind, phase III study of PAN (or placebo) + BTZ + dexamethasone (Dex). Methods: Pts with Rel or Rel/Ref MM (1-3 prior lines of therapy) were enrolled. Pts with BTZ-ref MM were not eligible. The study was comprised of 2 treatment phases, and follow up was to be continued during and after treatment until progressive disease or relapse. Treatment phase 1 consisted of eight 3-week cycles of PAN or placebo administered thrice weekly and BTZ administered twice weekly for 2 weeks. Dex was administered on days of and after BTZ. Pts who achieved clinical benefit proceeded to treatment phase 2, which consisted of four 6-week cycles with BTZ and Dex administered at a reduced frequency. Results: Preliminary demographic and blinded safety data from 536 randomized pts were available with treatment ongoing in 257 pts (47.9%). Median age was 63 years (32-84 y). Approximately half of pts (51.7%) received 2-3 prior lines of therapy and 57.3% received prior stem cell transplant. Any-grade adverse events (AEs) included thrombocytopenia (47.6%), diarrhea (45.7%), fatigue (32.6%), anemia (30.5%), constipation (24.8%), and nausea (24.4%). Common grade 3/4 AEs were thrombocytopenia (36.2%), diarrhea (14.5%), anemia (13.0%), fatigue (12.2%), neutropenia (11.4%), and hypokalemia (11.0%). Of interest, peripheral neuropathy was observed in 24.6% at any grade and 5.3% at grade 3/4. Conclusions: Preliminary analysis in 525 pts treated in PANORAMA 1 demonstrated a comparable safety profile to clinical experience with BTZ + Dex. The data monitoring committee recommended the study continue as planned. Enrollment completion is anticipated for Feb 2012 (N = 762). Updated blinded safety data will be presented.
Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT): Initial results from a phase I trial.
Authors: Shakeel Modak, Michael P. La Quaglia, Jorge A. Carrasquillo, Pat Zanzonico, Catherine Enero, Neeta Pandit-Taskar, Hye Jin Kang, Nai-Kong V. Cheung
Journal: Journal of Clinical Oncology (2013)

3033 Background: DSRCT, a rare sarcoma of adolescents and young adults usually arising from the peritoneum, is lethal in &gt;80% of patients despite aggressive multimodality therapy. Recurrences often present as multifocal peritoneal implants, making it uniquely suited for intraperitoneal (IP) targeting. We hypothesized that targeted radiotherapy may improve local control and reduce relapses. IP RIT, by virtue of prolonged residence time and slow transfer to the circulation, may selectively target IP DSRCT while minimizing organ toxicity. The anti-4Ig-B7H3 murine monoclonal antibody 8H9 binds to 96% of primary DSRCT (Med Pediatr Oncol 39:547). 131 I-8H9 injected intra-Ommaya is safe (J Neurooncol 97:409). Methods: We initiated a phase I study to test the safety of IP RIT with 131 I-8H9. Cohorts of 3-6 patients were treated with 131 I-8H9 at escalated doses from 30mCi/m 2 -60mCi/m 2 as a single IP injection. A tracer dose of 2mCi 124 I-8H9 was given IP before 131 I-8H9 to acquire PET images and biodistribution data. Pharmacokinetics (PK) was studied using serial blood draws. Results: 15 heavily prior-treated patients: 13 with DSRCT, 2 with rhabdomyosarcoma received 30, 40, 50mCi/m 2 131 I-8H9 (3 at each dose level) or 60mCi/m 2 (n=6). Dose-limiting toxicity was not seen. Three patients (n=1 each) had transient, self-limiting, possibly therapy-related grade 3 toxicities: neutropenia, hepatic transaminase elevation and thrombocytopenia. No patient required hematopoietic stem cell rescue. Blood half life was 32.5±11.5h (n=12) and mean peritoneal residence time was 14.6h (n=3). Mean absorbed dose to blood based on blood sampling was 0.56±0.21 rad/mCi (n=14). Mean absorbed doses (rad/mCi) to kidney, liver, lung and spleen were 1.72, 1.92, 0.64 and 1.03 respectively (n=3). Dehalogenation was insignificant: &gt;80% iodine remained protein-bound in blood (n=10). 6/7 DSRCT patients treated without evaluable disease remain in remission at a median of 11.1 months post 131 I-8H9. Conclusions: IP 131 I-8H9 was safe and 124 I-8H9 provided valuable PK and dosimetry data. Since maximum tolerated dose was not reached we have expanded patient accrual to a planned dose of 90mCi/m 2 . Clinical trial information: NCT01099644.
Integrated Molecular Characterization of Uterine Carcinosarcoma
Authors: Andrew D. Cherniack, Hui Shen, Vonn Walter, Chip Stewart, Bradley A. Murray, Reanne Bowlby, Xin Hu, Shiyun Ling, Robert A. Soslow, Russell R. Broaddus, Rosemary E. Zuna, Gordon Robertson, Peter W. Laird, Raju Kucherlapati, Gordon B. Mills, John N. Weinstein, Jiashan Zhang, Rehan Akbani, Douglas A. Levine, Rehan Akbani, Adrian Ally, J. Todd Auman, Miruna Balasundaram, Saianand Balu, Stephen B. Baylin, Rameen Beroukhim, Tom Bodenheimer, Faina Bogomolniy, Lori Boice, Moiz S. Bootwalla, Jay Bowen, Reanne Bowlby, Russell Broaddus, Denise Brooks, Rebecca Carlsen, Andrew D. Cherniack, Juok Cho, Eric Chuah, Sudha Chudamani, Kristian Cibulskis, Melissa Cline, Fanny Dao, Mutch David, John A. Demchok, Noreen Dhalla, Sean Dowdy, Ina Felau, Martin L. Ferguson, Scott Frazer, Jessica Frick, Stacey Gabriel, Julie M. Gastier-Foster, Nils Gehlenborg, Mark Gerken, Gad Getz, Manaswi Gupta, David Haussler, D. Neil Hayes, David I. Heiman, Julian Hess, Katherine A. Hoadley, Robert Hoffmann, Robert A. Holt, Alan P. Hoyle, Xin Hu, Mei Huang, Carolyn M. Hutter, Stuart R. Jefferys, Steven J.M. Jones, Corbin D. Jones, Rupa S. Kanchi, Cyriac Kandoth, Katayoon Kasaian, Sarah Kerr, Jaegil Kim, Phillip H. Lai, Peter W. Laird, Eric Lander, Michael S. Lawrence, Darlene Lee, Kristen M. Leraas, Ignaty Leshchiner, Douglas A. Levine, Tara M. Lichtenberg, Pei Lin, Shiyun Ling, Jia Liu, Wenbin Liu, Yuexin Liu, Laxmi Lolla, Yiling Lu, Yussanne Ma, Dennis T. Maglinte, Marco A. Marra, Michael Mayo, Shaowu Meng, Matthew Meyerson, Piotr A. Mieczkowski, Gordon B. Mills, Richard A. Moore, Lisle E. Mose, Andrew J. Mungall, Karen Mungall, Bradley A. Murray, Rashi Naresh, Michael S. Noble, Narciso Olvera, Joel S. Parker, Charles M. Perou, Amy H. Perou, Todd Pihl, Amie J. Radenbaugh, Nilsa C. Ramirez, W. Kimryn Rathmell, Jeffrey Roach, A. Gordon Robertson, Sara Sadeghi, Gordon Saksena, Helga B. Salvesen, Jacqueline E. Schein, Steven E. Schumacher, Hui Shen, Margi Sheth, Yan Shi, Juliann Shih, Janae V. Simons, Payal Sipahimalani, Tara Skelly, Heidi J. Sofia, Matthew G. Soloway, Robert A. Soslow, Carrie Sougnez, Chip Stewart, Charlie Sun, Angela Tam, Donghui Tan, Roy Tarnuzzer, Nina Thiessen, Leigh B. Thorne, Kane Tse, Jill Tseng, David J. Van Den Berg, Umadevi Veluvolu, Roel G.W. Verhaak, Doug Voet, Amanda von Bismarck, Vonn Walter, Yunhu Wan, Zhining Wang, Chen Wang, John N. Weinstein, Daniel J. Weisenberger, Matthew D. Wilkerson, Boris Winterhoff, Lisa Wise, Tina Wong, Ye Wu, Liming Yang, Jean C. Zenklusen, Jiashan (Julia) Zhang, Hailei Zhang, Wei Zhang, Jing-chun Zhu, Erik Zmuda, Rosemary E. Zuna
Journal: Cancer Cell (2017)
SIGNIFICANT MITRAL REGURGITATION IN PATIENTS UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: EVOLUTION AND IMAGING PREDICTORS OF IMPROVEMENT
Authors: Olivier Chiche, Josep Rodés-Cabau, Campelo-Parada Francisco, Ander Regueiro, Barria Alberto, Rodriguez-Gabella Tania, Robert DeLarochellière, Jean-Michel Paradis, Eric Dumont, Daniel Doyle, Siamak Mohammadi, Sebastien Bergeron, Philippe Pibarot, Jonathan Beaudoin
Journal: Journal of the American College of Cardiology (2017)
RETINOPATHY AND RISK OF SUDDEN CARDIAC DEATH: THE ARIC STUDY
Authors: Sunil Kumar Agarwal, Nona Sotoodehnia, Faye L. Norby, Kunihiro Matsushita, Lin Chen, Barbara Klein, Ronald Klein, Silvana Lawvere, Wayne Rosamond, Wong T. Yin, Jagat Narula, Aaron Folsom, Josef Coresh, Gerardo Heiss
Journal: Journal of the American College of Cardiology (2017)
Expression of neurotrophins and their receptors in adult sarcomas.
Authors: Elke Malenke, Christiane Dorn, Stefan Wirths, Martin Rudolf Mueller, Lothar Kanz, Hans-Georg Kopp
Journal: Journal of Clinical Oncology (2013)

10562 Background: Neurotrophins (NT) influence proliferation, survival, death, and differentiation by binding Tropomyosin-related kinase (Trk) receptors and p75 NTR (CD271). While the three Trk-receptors TrkA, TrkB, and TrkC display specific binding to their ligands, i.e. TrkA to NGF (nerve growth factor), TrkB to BDNF (brain-derived neurotrophic factor), NT4/5 (neurotrophin 4/5) and TrkC to NT3 (neurotrophin 3), CD271 shows low affinity to all neurotrophins. Notably, CD271 has been suggested as marker for the prospective isolation of bone marrow mesenchymal stromal cells (MSC), and rhabdomyosarcomas have previously been found to express neurotrophins and NT receptors. Methods: RNA was isolated from sarcoma cell lines and freshly obtained sarcoma (src) cells from patients after surgical resection. RNA was reverse transcribed and cDNA products underwent PCR analysis with specific primers. Furthermore, cell lines from the same primary tissues were established and treated with doxorubicin. Effects of K252a (Trk receptor inhibitor), Pep5 (CD271-Inhibitor), and neurotrophins on sarcoma cell proliferation and survival were analyzed. Results: An array of freshly obtained clinical src samples (n=10 each subtype) was screened for expression of NT3, NT4/5, BDNF, NGF as well as TrkA, TrkB, TrkC, and CD271. Interestingly, src subtype-specific expression patterns were observed. In the established cell lines, K252a increased doxorubicin-induced tumor cell death, while CD271-Inhibitor Pep5 enhanced proliferation in doxorubicin treated cells, especially under serum free conditions and when combined with BDNF and NGF. Conclusions: NT and NT receptors are expressed on all adult src samples screened in this study. Chemotherapy resistant liposrc as well as myxofibrosrc samples displayed the strongest expression of NT3 as well as TrkB, TrkC, and CD271. The concomitant expression of NT and their receptors suggests autocrine self-stimulation, which may propagate survival, proliferation, and treatment resistance. NT receptor tyrosine kinases may represent an interesting therapeutic target in adult src.
LEFT VENTRICULAR END-DIASTOLIC PRESSURE PREDICTS OUTCOMES IN PATIENTS WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION INDEPENDENTLY OF LEFT VENTRICULAR SYSTOLIC FUNCTION
Authors: Daiga Saito, Ippei Watanabe, Rine Nakanishi, Mikihito Toda, Hideo Amano, Ryo Okubo, Takayuki Yabe, Takanori Ikeda
Journal: Journal of the American College of Cardiology (2017)
EFFICACY AND SAFETY OF EDOXABAN IN PATIENTS WITH ATRIAL FIBRILLATION AND ACTIVE MALIGNANCY: AN ANALYSIS OF ENGAGE AF – TIMI 48 RANDOMIZED CLINICAL TRIAL
Authors: Christina Fanola, Christian Ruff, Sabina Murphy, James Jin, Anil Duggal, Michele Mercuri, Elliott Antman, Eugene Braunwald, Robert Giugliano
Journal: Journal of the American College of Cardiology (2017)
CHRONOTROPIC INCOMPETENCE AND LONG-TERM RISK OF HEART FAILURE: THE HENRY FORD EXERCISE TESTING PROJECT
Authors: Waqas Qureshi, Amjad Ahmed, Michael Blaha, Clinton Brawner, Jonathan Ehrman, Daniel Kupsky, Steven Keteyian, Haitham Ahmed, Mouaz Al-Mallah
Journal: Journal of the American College of Cardiology (2017)
David Almond Pemberton
Authors: Mary T Higgins
Journal: BMJ (2017)

David Almond Pemberton was born in Devon, brought up in south Yorkshire, and educated in High Storrs Grammar School for Boys in Sheffield. He studied medicine at Edinburgh University and gained many distinctions. He completed his preregistration year at Leith Hospital and Roslynlee Hospital. He started his psychiatric training at the Crichton Royal Hospital, Dumfries, and completed it in the Birmingham scheme at Shelton Hospital in Shrewsbury. …
IMPACT OF SINGLE VERSUS DUAL ANTI PLATELET THERAPY ON EARLY OUTCOMES IN WOMEN UNDERGOING TRANSCATHETER AORTIC VALVE REPLACEMENT: FROM THE WIN-TAVI REGISTRY
Authors: Jaya Chandrasekhar, Alaide Chieffo, Anna Petronio, Samantha Sartori, Julinda Mehilli, Thierry Lefevre, Patrizia Presbitero, Piera Capranzano, Didier Tchetche, Alessandro Iadanza, Gennaro Sardella, Nicolas Van Mieghem, Emanuele Meliga, Nicolas Dumonteil, Chiara Fraccaro, Daniela Trabattoni, Ghada Mikhail, Samin Sharma, M.C. Ferrer, Christoph Naber, Peter Kievit, Michela Faggioni, Usman Baber, Marie Morice, Roxana Mehran
Journal: Journal of the American College of Cardiology (2017)
Time Course Studies of the Progeny of Barcoded CD34+ Human Cord Blood Cells Generated in Transplanted NOD/SCID-IL2Rγ−/− Mice Unveil the Clonal Dynamics of Short Term, Intermediate Term and Long Term Repopulating Cells
Authors: Alice M.S. Cheung, Long V. Nguyen, Annaick Carles, Paul H. Miller, Philip A Beer, Pawan Pandoh, David Knapp, Kiran Dhillon, Kane Tse, Thomas Zeng, Yongjun Zhao, Martin Hirst, Connie J. Eaves
Journal: Blood (2012)
COMPARISON OF ACUTE ELASTIC RECOIL BETWEEN COREVALVE AND SAPIEN 3 VALVES IN TRANSCATHETER AORTIC VALVE REPLACEMENT
Authors: Yash Jobanputra, Kesavan Sankaramangalam, Krishna Kandregula, Kinjal Banerjee, Brandon Jones, Stephanie Mick, Amar Krishnaswamy, Maan Fares, Samir Kapadia
Journal: Journal of the American College of Cardiology (2017)
QUANTITATIVE DISTINCTION OF LV MYOCARDIUM CLASSIFIED BY PRESENCE OR ABSENCE OF FIBROTIC CHANGE AND/OR HYPERTROPHIC CHANGE CONFIRMED BY CARDIAC MAGNETIC RESONANCE IN HYPERTROPHIC CARDIOMYOPATHY AND 2D SPECKLE TRACKING TTE
Authors: Nobusada Funabashi, Hiroyuki Takaoka, Koya Ozawa, Yoshio Kobayashi
Journal: Journal of the American College of Cardiology (2017)